文章核心观点 - 强生公司宣布其生物制剂TREMFYA®在III期克罗恩病临床试验中达到了所有主要和次要终点指标 [1][2][3] - TREMFYA®在克罗恩病治疗中展现出良好的疗效和安全性,有望成为唯一一种能够提供皮下和静脉注射两种给药途径的IL-23抑制剂 [2][3] - 该结果将在即将召开的医学会议上公布,并将提交给监管机构 [4] 根据目录分别总结 TREMFYA®在克罗恩病中的临床试验 - GRAVITI是一项随机、双盲、安慰剂对照的III期临床试验,评估TREMFYA®皮下给药方案在中重度活动性克罗恩病患者中的疗效 [6] - GALAXI是一项II/III期临床试验项目,评估TREMFYA®在中重度活动性克罗恩病患者中的疗效和安全性,包括与STELARA®的对照研究 [7] 克罗恩病的概况 - 克罗恩病是一种慢性肠道炎症性疾病,目前尚无治愈方法 [8][9] - 该病影响了约300万美国人和400万欧洲人,症状包括腹痛、腹泻、体重下降等 [8][9] TREMFYA®的机制和适应症 - TREMFYA®是强生公司开发的首个完全人源化的双效单克隆抗体,通过抑制IL-23发挥治疗作用 [10] - TREMFYA®已获批用于治疗中重度斑块状银屑病和活动性银屑病性关节炎 [11]

Loading...Loading...As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.Mega-cap stocks, known for their large market capitalizations and relatively stable performances, are often considered safe havens during uncertain times. However, even within this category, there are bargains to be found. Moreover, even in times wh ...

Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatmentsVIENNA, June 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa scor ...

24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 studyMADRID, June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable ...

会议主要讨论的核心内容 - 公司在新的组织架构下,通过创新药和医疗器械业务,致力于为患者带来变革性创新 [10][11] - 公司在全球范围内保持领先地位,在欧洲和中国市场表现出色 [19][20][23] - 公司在研发方面取得了非常出色的成绩,90%的临床项目都取得成功,并在多个新兴技术领域如双特异性抗体、抗体偶联药物、放射性药物等保持领先地位 [33][35][36][38] - 公司大量投入人工智能技术,在临床试验设计、患者招募、生产制造等环节取得显著成效 [40][41][42][44] - 公司的多发性骨髓瘤和免疫学业务是公司的核心业务,TREMFYA有望在溃疡性结肠炎和克罗恩病领域取得成功 [48][51][52] - 公司在中枢神经系统领域也有多款新机制药物正在开发,包括用于治疗抑郁症的SPRAVATO和阿尔茨海默病的新疗法 [68][69][74] 问答环节重要的提问和回答 问题1 **Chris Shibutani 提问** 公司在新的组织架构下,如何把握战略优势 [8] **Jennifer Taubert 回答** 公司通过创新药和医疗器械业务,全力投入解决最大的医疗需求,并利用公司的全球布局和资源优势,有望取得持续高于市场的增长 [10][11][12] 问题2 **Chris Shibutani 提问** 如何看待美国通过的降药价法案(IRA)对公司的影响 [13] **Jennifer Taubert 回答** 公司认为IRA对创新不利,但公司的业务结构较为多元化,受影响的主要是生命周期较后期的产品,对公司整体增长影响有限,公司有信心在这一环境下继续保持领先地位 [15][16][17] 问题3 **Chris Shibutani 提问** 公司在中国市场的发展情况如何 [22] **Jennifer Taubert 回答** 中国是公司前10大市场,公司持续投资并取得国家医保准入,看好中国市场的增长潜力 [23] **John Reed 回答** 公司在中国建立了近900人的临床开发团队,中国患者占公司整体临床试验招募的20%,并通过上海创新中心积极引进中国生物技术公司的创新 [25][26][29]

Johnson & Johnson (NYSE:JNJ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 12, 2024 2:00 PM ET Company Participants Jennifer Taubert - Executive Vice President, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's get started. Thank you, everybody who's here. It's not exactly the weather and climate environment, it's been a big challenge here. Chris Shibutani from the Gol ...

Loading...Loading...During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.Below a ...

The integration of AI and healthcare is well underway.The human lifespan has increased dramatically since the start of the 17th century, from an average of just 30-40 years to over 70 years today. However, the next leap forward in longevity could be even more profound, driven by the transformative power of artificial intelligence (AI).AI has the potential to revolutionize healthcare and aging research, enabling scientists to uncover groundbreaking insights into the biological processes underlying aging and ...

Maintaining stability and security in investment portfolios is vital in an adverse macroeconomic environment. For instance, the current higher-for-longer interest rate environment coupled with other volatile macro elements may lead stocks into an unexpected and sudden downfall.Therefore, investors often seek out recession-proof stocks when escaping turbulent financial markets. These stocks have fundamentals that allow them to survive and flourish during difficult times — a fundamental and progressive resili ...

文章核心观点 - 约翰逊 & 约翰逊(JNJ)股价在最新交易中下跌1.24%,低于标普500指数1.19%的涨幅[1] - 过去一个月,该公司股价下跌0.62%,低于医疗行业3.54%和标普500指数3.35%的涨幅[2] - 分析师预计该公司将在2024年7月17日公布的季度财报中,每股收益为2.73美元,同比下降2.5%;营收为223.7亿美元,同比下降12.38%[3] - 全年来看,分析师预计该公司每股收益为10.64美元,同比增长7.26%;营收为882.8亿美元,同比下降5.1%[4] 根据相关目录分别进行总结 公司表现 - 约翰逊 & 约翰逊股价在最新交易中下跌1.24%,低于大盘涨幅[1] - 过去一个月,该公司股价下跌0.62%,低于医疗行业和大盘的涨幅[2] - 分析师预计该公司将在2024年7月公布的季度财报中,每股收益和营收均同比下降[3] - 全年来看,该公司每股收益预计增长7.26%,营收预计下降5.1%[4] 行业表现 - 医疗行业过去一个月涨幅为3.54%,高于该公司股价下跌0.62%[2] - 大盘标普500指数过去一个月涨幅为3.35%,高于该公司股价下跌0.62%[2] - 该公司所属的大型制药行业目前在所有行业中排名靠后,位于底部41%[10][11]